pH-weighted MRI in Multiple Sclerosis: A Surrogate Marker of Tissue Metabolic Stress

July 9, 2020 updated by: NYU Langone Health
Twenty subjects (10 patients and 10 age-matched control volunteers) will be recruited for this study. MRI scans will take place on a 3T MRI Scanner (Skyra or Prisma, Siemens Medical Solutions) located at The NYU Center for Biomedical Imaging. MRI scans will consist of a 1-hour brain scan for both patients and controls. In the first 6 months of the study, investigators will develop and test a uMT-based APT imaging for brain tissue pH measurement and use a hypercapnia paradigm to validate the tissue pH changes between breathing room air and 5% CO2 (by increasing tissue acidity) inhalation. With implementation of hypercapnia MRI, pH-weighted imaging will be validated for its robustness and reproducibility.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

The contrast agent (Gd-DTPA, Gadavist) will be injected intravenously (IV) in the arm (patients only). The IV will be inserted by qualified medical professional at CBI. This contrast agent will be standard dose in accordance with its FDA approved labeling and dosing. Controls will NOT be administered the contrast agent.

Study Type

Observational

Enrollment (Actual)

4

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • United States
    • New York
      • New York, New York, United States, 10016
        • New York University School of Medicine

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 65 years (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Patients with relapse-remitting multiple sclerosis from NYU Langone Health and age-matched healthy volunteers recruiting using previous database of volunteers

Description

Inclusion Criteria:

  • Healthy male or female non-MS control volunteers

Exclusion Criteria:

  • Medically unstable or with cardiac, pulmonary, hematological, renal, or hepatic dysfunction.
  • Current or past DSM-IV diagnosis of major depression, bipolar and psychotic disorders.
  • Contraindications for MRI, including
  • Intracranial clips
  • Metal implants
  • External metallic devices/objects/clips within 10mm of the head
  • Suspected or confirmed metal in the eyes (history of welding or similar activity)
  • Claustrophobia
  • Cardiac pacemaker or pacing wires
  • Pregnancy - Pregnancy tests will be offered to women of childbearing age at no cost to the subject
  • History of moderate to severe head injury, stroke, and seizures.
  • Alcoholism or drug dependency.

  • Renal or liver disease as this may cause concerns related to Gd-DTPA contrast agent.

    • Allergy to the contrast agent Gadolinium
    • Relapses or steroid therapy in patient at or in the month preceding the study
    • Patients only

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Multiple Sclerosis
Other: MRI Scan
MRI scans will consist of a 1-hour brain scan for both patients and controls.
Healthy Volunteer
10 age-matched control volunteers
Other: MRI Scan
MRI scans will consist of a 1-hour brain scan for both patients and controls.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
pH measurements
Time Frame: 20 Minutes
The pH will be estimated based on the calibration methods of quantification of exchange as a function of saturation time (QUEST)32 and its ratiometric analysis (QUESTRA) 33.
20 Minutes

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

NYU Langone Health

Investigators

  • Principal Investigator: Yulin Ge, MD, New York University Medical School

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

May 1, 2017

Primary Completion (Actual)

August 10, 2018

Study Completion (Actual)

August 10, 2018

Study Registration Dates

First Submitted

January 19, 2017

First Submitted That Met QC Criteria

January 19, 2017

First Posted (Estimate)

January 23, 2017

Study Record Updates

Last Update Posted (Actual)

July 13, 2020

Last Update Submitted That Met QC Criteria

July 9, 2020

Last Verified

July 1, 2020

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 16-01434

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

Yes

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Multiple Sclerosis

Clinical Trials on MRI Scan

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Switzerland

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe